3MO LDH isoforms shape the immune microenvironment and impact treatment response and survival in metastatic melanoma

Le résumé fourni par la source

TC) and using the combined positive score (CPS).TILs or PD-L1 increase was defined by an absolute change of 1 %.Results: Baseline TILs > 1% were observed in 51.5% of pts and this proportion decreased in the 3 arms at W6. Baseline PD-L1 IC > 1% was observed in 57.0% of pts and this proportion increased in the 3 arms at W6, with a more pronounced increase in the two arms with durva (Arm 2 and 3).In 32.2% of pts, there was no tumor at W6. Increase of PD-L1 at W6 and absence of tumor at W6 were associated with a higher rate of pCR at surgery, particularly in the arms with durva.Table: 2O All Arm 1 Arm 2 Arm 3 n 135 45 45 45 pts, % B: PD-L1 negative* 58.5 57.8 57.8 60.0 W6: no tumor 32.2 13.5 46.3 34.9 W6: TILs increase 14.0 16.2 12.2 14.0 W6: PD-L1 IC increase 42.7 31 48 48 pCR rate, % All pts 28.9 17.8 33.3 35.6 B: PD-L1 negative* 24.0 3.8 34.6 33.3 W6: no tumor 48.7 40.0 47.4 53.3 W6: TILs increased 17.6 0.0 20.0 33.3 W6: PD-L1 IC increased 24.0 0.0 46.0 40.0 TILs: pts, % B: TILs 1% 51.5 51.2 50.0 53.3 W6: TILs 1% 26.8 28.1 27.3 25.0 PD-L1: pts, % B: PD-L1 IC 1% 57.0 57.8 57.8 55.6 W6: PD-L1 IC 1% 70.5 48.3 85.7 82.1 B: PD-L1 TC 1% 22.2 24.4 17.8 24.4 W6: PD-L1 TC 1% 29.9 13.8 42.9 37.0 B: PD-L1 CPS 1% 39.3 37.8 40.0 40.0 W6: PD-L1 CPS 1% 54.5 37.9 66.7 63.0 B, baseline; pts, patients; W6, week 6.*Stratification factor.Conclusions: In pts treated with iSBRT+durva, PD-L1 increase or absence of tumor at W6 is associated with higher pCR rate at surgery. Clinical trial identification: NCT03875573.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.